{"title": "David I Quinn, MD | Keck School of Medicine of USC", "author": null, "url": "https://keck.usc.edu/faculty-search/david-i-quinn/", "hostname": "keck.usc.edu", "description": null, "sitename": "Keck School of Medicine of USC | Leaders in medical education, research and patient care", "date": "2018-07-31", "cleaned_text": "David I Quinn Contact Castle Connolly Medical: America's Top Doctors, 2010 USC Norris Cancer Center and Hospital: The Spirit of Norris Award, 2002 Royal Australasian College of Physicians: Vincent Fairfax Family Fellowship, 2001 National Health and Medical Research Council of Australia: Neil Hamilton Fairley Fellowship, 2000-2003 St. Vincent's Clinic Foundation: The David Wilson Travelling Fellowship, 2000 Postgraduate Medical Council of New South Wales: Distinguished Contribution Award, 2000 National Health and Medical Research Council of Australia: Postgraduate Medical Scholarship, 1996-1999 University of New South Wales: Honours First Class Bachelor of Medicine, Bachelor of Surgery, 1987 University of New South Wales: Gordon Lowe Memorial Prize, 1987 Albumin levels predict prognosis in advanced renal cell carcinoma treated with tyrosine kinase inhibitors: to high-volume surgeons and the opportunity cost of in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/37080171) Cell-free DNA Methylation as a Predictive Biomarker of Response to Neoadjuvant Chemotherapy for Patients with Muscle-invasive Bladder Cancer in SWOG S1314 Eur Urol Oncol. 2023 Apr 20. . View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/37087309) Bone Biomarkers and Subsequent Survival in Men with Hormone-sensitive Prostate Cancer: Results from the SWOG S1216 Phase 3 Trial of Androgen Deprivation Therapy with or Without Orteronel Eur Urol. 2023 Apr 19. . View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/37085425) Combination Treatment with Sipuleucel-T and Abiraterone Acetate or Enzalutamide for Metastatic Castration-Resistant Prostate Cancer: STAMP and STRIDE Trials Clin Cancer Res. 2023 Apr 14. . View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/37058234) FORT-1: Phase II/III Study of Rogaratinib Versus Chemotherapy in Patients With Locally Advanced or Metastatic Urothelial Carcinoma Selected Based on FGFR1/3 2023 01 20; 41(3):629-639. View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/36240478) II Trial of Guadecitabine plus Atezolizumab in Metastatic Urothelial Carcinoma Progressing after Initial Immune Checkpoint Therapy Clin Cancer Res. 2023 06 patients with HER2-mutant advanced tract cancers Nat 41(3):640-650. . View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/35984996) Outcomes of temporary mechanical circulatory support in cardiogenic shock due to end-stage heart failure J Intensive Care Soc. 2022 May; 23(2):170-176. . View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/35615244) Non-Invasive Profiling of Advanced Prostate Cancer via Multi-Parametric Liquid Biopsy and Radiomic Analysis Int J Feb 25; 23(5). . View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/35269713) Management Trends and Outcomes of Patients Undergoing Radical Cystectomy for Urothelial Carcinoma of the Bladder: Evolution of the University of Southern California Experience over 3,347 Cases J Urol. Challenges aneurysm Clin Radiol. 2022 11; 77(11):803-809. . View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/36057463) Integration of Liquid Biopsies in Clinical Management of Metastatic Prostate Cancer Curr Oncol Rep. 2022 II, Single-arm Trial of Sunitinib and Erlotinib in Advanced versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/36055304) Health-related Quality Life of Patients with Locally Advanced or Metastatic Urothelial Cancer Treated with Enfortumab Vedotin after Platinum and PD-1/PD-L1 Inhibitor Therapy: Results from Cohort 1 of the Phase EV-201 Clinical Trial Eur Urol. 2022 05; from a therapeutic wilderness to so many options; a guide to practice in a changing landscape Ann Oncol. 2022 03; 33(3):242-243. . Pembrolizumab in Advanced Urothelial Cancer: Results from the KEYNOTE-045 View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/35247908) Collaborative study from the Bladder Cancer Advocacy Network for the genomic analysis of metastatic urothelial cancer [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/36333289) Living with a left ventricular assist device: Capturing recipients experiences using group concept mapping software PLoS One. 2022; 17(9):e0273108. . View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/36129928) Open surgical replacement of the descending thoracic and thoracoabdominal aorta in patients with confirmed Marfan using CT radiomic signatures for predicting CD8-T cell infiltration and PD-L1 expression in renal cell carcinoma Eur J Radiol Open. 9:100440. 40(28):3301-3309. . View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/35446628) Cardiac Power Output Index and Severe Primary Graft Dysfunction After Heart Transplantation J Cardiothorac Vasc Anesth. 2021 Feb; of brentuximab vedotin in relapsed/refractory germ cell tumors Invest 12; 39(6):1656-1663. . View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/34031784) Pathophysiology of severe orthotopic heart Clin Transplant. 2021 09; 35(9):e14398. . carcinoma of the urothelium - an NCI-CTEP sponsored: California Cancer Consortium trial, NCI 6879 Invest New Drugs. 2021 06; 39(3):812-820. . View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/33409898) ATLAS trial of adjuvant axitinib in patients with renal cell carcinoma: subgroup analyses with focus on axitinib dosing and racial advanced urothelial carcinoma (EV-201): in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/33991512) A randomized phase IIa study of quantified bone scan response in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223 dichloride oxidase inhibitor phenelzine in 08 19; 385(8):683-694. . View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/34407342) Baseline Circulating Tumor Cell Count as a Prognostic Marker of PSA Response and Disease Progression in Metastatic Castrate-Sensitive Prostate Cancer T-cell Populations as Prognostic Biomarkers to Combination Immunotherapy Identification of 22 susceptibility loci associated with testicular germ cell tumors Nat 10(2). . View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/32694189) Evaluating Changes in Immune Function and Bone Microenvironment During Radium-223 Treatment of Patients with Castration-Resistant Prostate Cancer 2020 Sep; in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/32366119) prostate targeted therapy Res Pract. 2020 Jun; 216(6):152967. . View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/32362422) Comparative Survival of Asian and White Metastatic Castration-Resistant Prostate Cancer Men Treated With Docetaxel 2020 Apr; 4(2):pkaa003. Protocol for a multi-centre, definitive randomised controlled trial of the effectiveness of Individual Placement and Support for employment support among people with alcohol and drug dependence Trials. 2020 Feb 11; 21(1):167. . View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/32046765) Hyperphosphatemia Secondary Growth Factor Receptor 1-3 Inhibitor Infigratinib (BGJ398) Is Associated 12; Safety and efficacy of an antibody-drug conjugate directed against T cell immunoglobulin mucin-1 in advanced renal cell carcinoma Invest New Drugs. 2020 12; 38(6):1807-1814. . View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/32472319) Programmed Death 1 and Programmed Death Ligand 1 Inhibitors in Advanced and Recurrent Urothelial [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/32146152) Use of Wearable Activity Tracker in Patients With Cancer Undergoing Chemotherapy: Toward Evaluating Risk of Unplanned Health Care Encounters JCO Clin Cancer Inform. 2020 09; 4:839-853. . View in Survival of African-American and Caucasian men after sipuleucel-T immunotherapy: outcomes from the PROCEED registry Prostate Cancer Prostatic Dis. 2020 09; 23(3):517-526. . View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/32111923) Survival and risk group validation from SWOG S0925: a randomized phase II study of cixutumumab in new metastatic hormone-sensitive prostate cancer Prostate Cancer 2020 09; 23(3):486-493. . View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/32055002) Chemoradiation for Management of Locally Recurrent or Residual Bladder Cancer: A Case Series and Review of the Literature Clin Genitourin Cancer. 2020 08; 18(4):e473-e477. . View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/32044240) Eligibility Criteria and Endpoints in Metastatic Renal Cell Carcinoma Trials Am J Clin Oncol. 2020 08; 43(8):559-566. . View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/32398404) Clinical outcomes in men of diverse ethnic backgrounds with metastatic castration-resistant prostate cancer Ann Oncol. 2020 07; 31(7):930-941. 203(2):336-337. . View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/31661381) Cancer transcriptomic profiling from rapidly enriched circulating tumor cells Int J Cancer. 2020 05 15; 146(10):2845-2854. . View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/32037533) Randomized Double-Blind Study of Maintenance Pembrolizumab Versus Placebo After First-Line Chemotherapy in Patients With in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/32271672) to Potential underestimation of cerebrovascular events in the PROVENGE Registry for the Observation, Collection, and Evaluation of Experience Data Cancer. 2020 06 15; 126(12):2935-2937. . View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/32154908) Infigratinib in upper tract urothelial carcinoma versus urothelial carcinoma of the bladder and its association with comprehensive genomic profiling and/or cell-free DNA results Cancer. 2020 06 01; 126(11):2597-2606. . View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/32208524) Comparative prognostic treatment response assessments in mCRPC: PERCIST 10, RECIST 1. 1, and PSA 2020; 10(7):3254-3262. . View in of Single-Agent Enfortumab Vedotin in Patients With Nectin-4-Positive Solid Tumors, J 04 in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/32031899) Local Injection of Submicron Particle Docetaxel is Associated with Tumor Eradication, Reduced Systemic Toxicity and an Immunologic Response in Uro-Oncologic Xenografts Cancers (Basel). 2019 Apr 24; 11(4). . [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/31022918) Randomized Phase 2 Study Trebananib (AMG 386) with or without Continued Anti-Vascular Endothelial Growth Factor Therapy in Patients with Renal Cell Carcinoma Who Have Progressed on Bevacizumab, Pazopanib, Sorafenib, or Sunitinib - Results of Cancer. 2019 Feb 05; 3(1):51-61. . View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/30854497) Accurate blood pressure during movement: the Welch Allyn Connex [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/30586341) Radium-223 mechanism of action: implications for use in treatment combinations Nat Rev Urol. 2019 12; 16(12):745-756. . View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/31712765) Prediction of Time to Hormonal Treatment Failure in Metastatic Castration-Sensitive Prostate Cancer with 18F-FDG PET/CT 11; 60(11):1524-1530. . View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/30926649) p53 nuclear accumulation as an early indicator of lethal prostate cancer Br J Cancer. 2019 10; 121(7):578-583. . View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/31409910) Randomized Phase II Trial of Abiraterone Alone or With Dasatinib in Men With Metastatic . View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/31227432) A phase II study of the orally administered negative enantiomer of gossypol (AT-101), a BH3 mimetic, in patients with carcinoma Invest New Drugs. 2019 08; in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/31172443) Author Nature. 02; 566(7745):E11-E12. . View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/30755741) Association between precystectomy epithelial tumor marker response to neoadjuvant chemotherapy and oncological outcomes in urothelial bladder 2019 01; 37(1):1-11. . View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/30470611) Impact of timing of administration of bone supportive therapy on pain palliation from radium-223 Cancer Treat Res Commun. 2019; 18:100114. . View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/30529990) The society for immunotherapy of cancer consensus statement on immunotherapy for the treatment of advanced renal cell carcinoma (RCC) J Immunother Cancer. 2019 12 20; 7(1):354. . View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/31856918) Influence of the facility caseload on the subsequent survival of men with localized prostate cancer undergoing radical prostatectomy Cancer. 2019 11 01; 125(21):3853-3863. . View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/31398279) Phase 1 Trial of SBRT to the Prostate Fossa Survival of Black and White Men With Metastatic Castration-Resistant Prostate Cancer Treated With Docetaxel J 03 07; 4(5). . View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/30702443) Phase II California Cancer Consortium Trial of Gemcitabine-Eribulin Combination in Cisplatin-Ineligible Patients With Metastatic Urothelial vinflunine in advanced on bladder cancer: systemic therapy for metastatic bladder cancer World J Urol. 2019 Jan; 37(1):95-105. . View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/30238401) Real-world outcomes of sipuleucel-T treatment in PROCEED, a prospective registry of men with metastatic castration-resistant prostate cancer Cancer. 2019 12 01; 125(23):4172-4180. . View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/31483485) Impact of FDG PET Imaging for Expanding Patient Eligibility and Measuring Treatment Response in a Genome-Driven Basket Trial of the Pan-HER Kinase . View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/31548342) Validating the total illness burden index for prostate cancer (TIBI-CaP) in men with castration-resistant prostate cancer: data from TRUMPET Future Oncol. in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/29417827) Growth Factor-targeted Therapy in Renal Cell Carcinoma: A Systematic Review and Pooled Analysis Eur Urol. 2018 11; 74(5):611-620. . View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/29784193) Active Surveillance for Prostate Cancer: Are We Failing Latino Patients at a Large Safety Net Hospital? Clin Genitourin Cancer. 2018 08; 16(4):e719-e727.. View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/29483045) Low-dimensional dynamical characterization of human performance of cancer patients motion data Clin Biomech (BristolAvon). 2018 07; a Fibroblast Growth Factor Receptor 1-3 Inhibitor, in Patients with Previously Treated Advanced Urothelial Carcinoma with FGFR3 Alterations Cancer Discov. 2018 07; 8(7):812-821. . View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/29848605) Phase III Intergroup Trial of Adjuvant Androgen Deprivation With or Without Mitoxantrone Plus Prednisone in Patients With High-Risk Prostate Cancer After KEYNOTE-045: A Phase III Study of Pembrolizumab Versus Chemotherapy for Previously Treated Advanced Urothelial Cancer J in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/29590008) Axitinib versus placebo as an adjuvant treatment of renal cell carcinoma: results from the phase III, randomized ATLAS trial Ann Oncol. 2018 in Hormone-Sensitive Castration-Resistant Prostate Cancer and Association with Overall Survival Clin Cancer Res. 2018 10 01; 24(19):4662-4671. . View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/29858218) Bone turnover biomarkers identify unique prognostic risk groups in men with castration resistant prostate cancer and skeletal metastases: Results from SWOG S0421 Cancer Treat and HER3-mutant 08; 554(7691):189-194. . View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/29420467) Immunomodulation by Entinostat in Renal Cell Carcinoma Patients Receiving High-Dose Interleukin 2: A Multicenter, Single-Arm, Phase [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/28939740) Bevacizumab alone in combination with TRC105 for patients with refractory metastatic renal cell cancer Cancer. 2017 Dec 01; 123(23):4566-4573. . View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/28832978) The evolution of chemotherapy for the treatment of prostate cancer Ann Oncol. 2017 Nov 01; 28(11):2658-2669. . View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/29045523) Baseline Filtration Rate and Cisplatin- Induced Renal Toxicity in Urothelial Cancer Patients Clin Genitourin Cancer. 2017 Sep 06. Efficacy View in urothelial checkpoint inhibitors in advanced renal cell carcinoma: experience to date and future directions Ann Oncol. 2017 01; 28(7):1484-1494. . in patients with hepatic Housing Policies Show Promise in Reducing Secondhand Smoke Exposure Among Racially and Ethnically Diverse, Low-Income Seniors J Immigr Minor Health. 2017 12; 19(6):1281-1289. Use Criteria for 18F-FDG PET/CT in Restaging and Treatment Response Assessment of Malignant Disease J Nucl Med. 2017 12; 58(12):2026-2037. . View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/29025980) Validation of the Association of RECIST Changes With Survival in Men With Metastatic Castration-Resistant Prostate Cancer Treated II AEZS-108 in Castration- in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/28668277) salvage retroperitoneal and pelvic lymph node dissection for 'node-only' recurrent prostate cancer: technique and initial series and metastatic urothelial carcinoma: a 07; 389(10064):67-76. . View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/27939400) Comparative effectiveness colorectal cancer castration-resistant prostate cancer receiving docetaxel and Atrasentan versus docetaxel and placebo in a randomized phase III clinical trial (SWOG S0421) J Patient Rep Outcomes. 2017; 2:27. . View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/29951640) Isolation of exosomes by integrating acoustics and microfluidics Proc 114(40):10584-10589. . View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/28923936) Treatment registry for outcomes in patients with castration-resistant prostate cancer (TRUMPET): a methodology for real-world evidence and research Future Oncol. 2016 Dec; 12(23):2689-2699. . View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/27528114) What Medical, Urologic, and Radiation Oncologists Want from Molecular Imaging of Prostate Cancer J Nucl Med. 2016 Oct; 57(Suppl 3):6S-12S. . View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/27694176) AXIN2 expression predicts prostate cancer recurrence and regulates invasion and tumor growth Prostate. 2016 May; 76(6):597-608. . View at high-volume centers improves outcomes and lowers the costs of care for prostate cancer Prostate Cancer Prostatic Dis. 2016 Mar; 19(1):84-91. . View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/26666409) Epidermal Meta-Analysis Evaluating the Impact of Site of Metastasis on Overall Survival in Men With Castration-Resistant Prostate Cancer J Clin Oncol. 2016 05 10; 34(14):1652-9. . View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/26951312) Safety and feasibility of fasting in combination with platinum-based chemotherapy BMC Cancer. 2016 06 10; 16:360. . View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/27282289) Clinical use of cabozantinib in the treatment of advanced kidney cancer: efficacy, safety, and patient selection Onco First-Line Treatment of Patients With Intermediate- or Poor-Risk Germ Cell Tumors J Clin Oncol. 2016 20; 34(21):2478-83. . View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/27185842) Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of renal cell carcinoma J Immunother Cancer. 2016; 4:81. . View in With Ramucirumab or Icrucumab Second-Line Treatment Urothelial Carcinoma: An Three-Arm, 01; 34(13):1500-9. . View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/26926681) Guidelines for the definition of time-to-event end points in renal cell cancer clinical trials: results of the DATECAN project Ann . View Immune Checkpoint or Multiple Kinases N Engl J Med. 2015 Nov (eribulin, halichondrin B analog) during a phase I trial in patients with advanced solid tumors: a California Cancer Consortium trial Cancer Chemother Pharmacol. 2015 Nov; 76(5):897-907. . View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/26362045) Assessing the damage control resuscitation: development, drivers and direction Emerg Med Australas. receptor tyrosine kinase is a potential therapeutic target in renal cell carcinoma Br J Cancer. 2015 Aug 11; 113(4):616-25. . View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/26180925) Relapsed and refractory germ cell tumors: Finessing the rough end of a beautiful story Urol Oncol. 2015 Aug; 33(8):341-2. . View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/26094170) Radical Prostatectomy or External Beam Radiation Therapy vs No Local Therapy for Survival Benefit in Metastatic Prostate Cancer: A SEER-Medicare Analysis Study of Androgen Deprivation Combined With Cixutumumab Versus Androgen Deprivation Alone in Patients With New Metastatic Hormone-Sensitive Prostate Cancer J Clin 2015 33(5):245-60. . View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/25575714) Circulating tumor cell telomerase activity as a prognostic marker for overall survival in SWOG 0421: a phase III metastatic castration resistant prostate cancer trial Int J Cancer. 2015 Apr 15; 136(8):1856-62. . View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/25219358) Linsitinib (OSI-906) versus locally advanced or metastatic adrenocortical carcinoma: a double-blind, Apr; 16(4):426-35. . View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/25795408) Hypertension among patients with renal cell carcinoma receiving axitinib or sorafenib: analysis from the randomized phase III AXIS trial Target Oncol. 2015 Mar; 10(1):45-53. . View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/24595903) Association of overall survival with glycolytic activity of castrate-resistant prostate cancer metastases Radiology. 2015 Feb; 274(2):624-5. . View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/25625748) Current and recent clinical trials for perioperative systemic therapy for muscle invasive bladder cancer: a systematic review BMC Cancer. 2014 Dec 16; 14:966. . View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/25515347) Phase I, dose-escalation study of the targeted cytotoxic LHRH analog AEZS-108 in patients with castration- and taxane-resistant cancer Clin Cancer Res. 2014 Dec 15; 20(24):6277-83. . View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/25278449) A Phase II trial of a combination herbal supplement for men with biochemically recurrent prostate cancer Prostate Cancer Prostatic Dis. 2014 . View in View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/25456359) Oscillometric blood pressure: a clinicians J Am Soc Hypertens. 2014 Dec; 8(12):930-8. . View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/25492837) Phase I clinical trial of temsirolimus and vinorelbine in advanced solid tumors Cancer Chemother Pharmacol. 2014 Dec; 74(6):1227-34. . View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/25374407) Phase 2 trial of dovitinib in patients with progressive FGFR3-mutated or FGFR3 wild-type advanced urothelial carcinoma Eur J Dec; 50(18):3145-52. . View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/25457633) A randomized phase 2 trial of gemcitabine/cisplatin with or without cetuximab in patients with advanced urothelial carcinoma Cancer. 2014 Sep 01; 120(17):2684-93. . View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/24802654) Carboplatin's fourth decade: still its sweet spot Ann Oncol. 2014 Aug; 25(8):1457-8. . View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/24950978) Examining the management of muscle-invasive bladder cancer by medical oncologists in the United States Urol Oncol. 2014 Jul; 32(5):637-44. . View IGF-1/PKA to promote hematopoietic-stem-cell-based regeneration and reverse immunosuppression Cell Stem Cell. 2014 Jun 05; 14(6):810-23. . View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/24905167) Skate park injury: a new mechanism of sternoclavicular joint dislocation Emerg Med Australas. 2014 Jun; 26(3):316-7. . View in chemotherapy tumors Oncology (Williston Park). 2014 Jun; 28(6):498-500. . View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/25134324) Circulating tumor cell counts are prognostic of overall survival in SWOG S0421: a phase III trial of docetaxel with or without atrasentan for metastatic castration-resistant 10; 32(11):1136-42. . View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/24616308) Effect of mechanical behavior of the brachial artery on blood pressure measurement during cuff inflation and cuff deflation Blood Press Monit. 2014 Apr; 19(2):120. . View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/24618886) Serum biomarkers of bone metabolism in castration-resistant prostate cancer patients with skeletal metastases: results from J in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/24565955) Durable complete remission from prostate cancer with sipuleucel-T estrogen withdrawal [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/24331572) Novel tyrosine kinase inhibitors carcinoma Expert 2014 Jan; 7(1):67-73. . receptor-targeted therapy in squamous cell carcinoma of the penis: a report of 3 cases Urology. 2014 Jan; 83(1):159-65. View in sorafenib for metastatic renal cell carcinoma: phase 1/2 study J Immunother Cancer. 2014; 2:2. . View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/24829759) The differential expression of EphB2 and EphB4 receptor kinases in normal bladder and in transitional cell carcinoma of the bladder PLoS One. 2014; 9(8):e105326. . View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/25148033) Effect of gender on outcomes following radical cystectomy for urothelial carcinoma of the bladder: a Anticancer Ther. in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/24099865) therapy of prostate cancer 2013 muscle-invasive urothelial carcinoma of the bladder: a retrospective analysis from the University of Southern California. Urol Oncol. 2013 Nov; 31(8):1737-43. . View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/23141776) Differentiating mTOR inhibitors in renal cell carcinoma Cancer Treat Rev. 2013 Nov; 39(7):709-19. . Allergy. 2013 Sep; 68(9):1136-42. . View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/23924233) A phase 2 multicenter study of tivantinib (ARQ 197) monotherapy in patients with relapsed or refractory germ cell tumors Invest New Drugs. 2013 Aug; 31(4):1016-22. . View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/23417696) Baseline 18F-FDG PET/CT imaging biomarkers of overall survival in castrate-resistant metastatic prostate cancer J Med. in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/23785174) Docetaxel and atrasentan versus docetaxel and placebo for men with advanced castration-resistant prostate cancer (SWOG S0421): a randomised phase 3 Oncol. 2013 Aug; 14(9):893-900. . View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/23871417) Therapeutic windows and opportunity cost cast upon prostate cancer's fatal shore Ann Oncol. 2013 Jul; 24(7):1717-1720. . View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/23798673) Intermittent versus continuous androgen deprivation in prostate cancer N Engl J Med. 2013 Apr 04; 368(14):1314-25. . View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/23550669) Speeding dating debutantes in castration-resistant prostate cancer: 'plus or Feb; 24(2):270-272. . View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/23341479) ICUD-EAU on Bladder Cancer 2012: Chemotherapy for urothelial carcinoma-neoadjuvant and adjuvant settings Eur Urol. 2013 Jan; 63(1):58-66. . View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/22917984) Clinical cancer advances 2012: annual report on progress against cancer from the american society of clinical oncology J Clin Oncol. 2013 Jan 01; 31(1):131-61. . View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/23213095) cell carcinoma Biologics. 2013; 7:139-48. . View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/23788831) Small Oct; 39(5):615-8. . in metastatic or unresectable renal-cell carcinoma: a trial of gemcitabine/cisplatin plus bevacizumab or placebo in patients with malignant mesothelioma J Clin Oncol. 2012 Jul 10; 30(20):2509-15. . PET/CT in detection of occult metastatic disease in biochemical prostate cancer Med. 2012 Jul; 37(7):637-43. . View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/22691503) Immune response to sipuleucel-T in prostate cancer Cancers (Basel). 2012 Apr 18; 4(2):420-41. . View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/24213318) Blood cells and their use in active immunotherapy of prostate cancer Hum Vaccin Immunother. 2012 Apr; 8(4):528-33. . View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/22370509) A phase II study of YM155, a novel small-molecule suppressor of survivin, in 2012 . in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/21859898) Novel therapies for metastatic renal cell carcinoma: efforts to expand beyond the VEGF/mTOR signaling paradigm Mol Cancer Ther. 2012 Mar; 11(3):526-37. . View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/22351744) Factors influencing post-recurrence survival in bladder cancer following radical cystectomy BJU Mar; . View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/22184381) The role of surrogate markers in the management of men with metastatic castration-resistant 2011 Oct; 36(10):961-2. . View in phase II trial of gefitinib and pegylated IFNa in previously treated renal cell carcinoma Int J Clin Oncol. 2011 Oct; 16(5):494-9. . View in cancer Maturitas. Aug; 69(4):296-303. . View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/21621934) Experience Crit Hematol. 2011 78(1):24-32. . View sign: search for \"game cancer collaborative for low-income, with cancer Psychiatr Serv. 2011 Feb; 62(2):162-70. . View trial of pegylated liposomal Doxorubicin and docetaxel in patients with advanced Am J Clin Oncol. 2011 Feb; 34(1):27-31. . View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/20142723) Using molecular markers to help predict who will fail after radical prostatectomy Prostate Cancer. 2011; 2011:290160. . View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/22096655) Cabazitaxel in prostate a string Lancet. 2010 Oct 02; 376(9747):1119-20. . View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/20888974) Phase II study of Aflibercept (VEGF-Trap) in patients with recurrent or metastatic urothelial cancer, a California Cancer Consortium Trial Urology. 2010 Oct; 76(4):923-6. . View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/20646741) Clinical and correlative results SWOG S0354: a phase II trial of CNTO328 (siltuximab), a monoclonal antibody against interleukin-6, in chemotherapy-pretreated patients with castration-resistant prostate cancer Clin Cancer Res. 2010 Jun 01; 16(11):3028-34. . View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/20484019) Expert opinion on the use of first-line sorafenib in selected metastatic renal cell carcinoma patients Expert Anticancer Ther. 2010 Jun; 10(6):825-35. . View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/20553208) Mosaic vaccines elicit CD8+ T lymphocyte responses that confer enhanced immune coverage of diverse HIV strains in monkeys Nat Med. 2010 Mar; 16(3):324-8. . View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/20173754) Fasting and cancer treatment in humans: A case series report Aging (Albany NY). 2009 Dec 31; 1(12):988-1007. . View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/20157582) Phase II study of erlotinib in patients with locally advanced or metastatic how have we made a \"sow's ear\" out of a chemotherapy-sensitive tumor? Cancer. 2009 Nov 15; 115(22):5139-42.. View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/19645028) Targeted therapy in Med Oncol. 2009 Nov; 1(3):183-205. . View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/21789121) An evaluation of the completeness of reporting of childhood tuberculosis Eur Respir J. 2009 Jul; 34(1):176-9. . View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/19251788) A phase II trial of the Src-kinase inhibitor AZD0530 in patients with advanced castration-resistant prostate cancer: a California Cancer Consortium study Anticancer Drugs. 2009 Mar; 20(3):179-84. . View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/19396016) Adjuvant chemotherapy for locally advanced urothelial carcinoma: an overview of the USC experience World J Urol. 2009 Feb; 27(1):39-44. omeprazole on the pharmacokinetics and safety bortezomib in patients with advanced TRIALS - SOUTHWEST ONCOLOGY GROUP (SWOG) INNOVATIONS IN ADVANCED PROSTATE CANCER in biochemically recurrent prostate cancer: a California cancer consortium phase II trial Clin Genitourin Cancer. 2009 Jan; 7(1):43-50. . View II trial of paclitaxel, carboplatin and gemcitabine in patients with locally advanced carcinoma of the bladder J Urol. 2008 Dec; 180(6):2384-8; discussion 2388. . View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/18930256) phase study of high-dose calcitriol combined with mitoxantrone and prednisone 102(11):1601-6. . View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/18782306) Subclinical haemostatic activation and current surgeon volume predict bleeding with open radical retropubic prostatectomy BJU Int. 2008 Nov; Randomized controlled trial of collaborative care management of depression among low-income patients with cancer J Clin Oncol. 2008 Sep 20; 26(27):4488-96. . View Phase I/II study of GTI-2040 and capecitabine in patients with renal cell carcinoma Cancer Chemother Pharmacol. is an adverse prognostic factor for serous epithelial ovarian cancer and modulates cisplatin resistance in vitro Br J Cancer. 2008 Mar 25; 98(6):1085-93. . View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/18349819) The AKT inhibitor biochemically recurrent prostate cancer: a phase II consortium trial Clin alpha-interferon in metastatic renal cancer: a phase II study of the California Cancer Consortium J Cancer Res Clin Oncol. 2007 Oct; 133(10):705-11. . View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/17508219) Improving treatment of depression among low-income patients with cancer: the design of the ADAPt-C study Gen Hosp Psychiatry. 2007 May-Jun; 29(3):223-31. . View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/17484939) Pain management, supportive and palliative care in patients with renal cell carcinoma BJU Int. 2007 May; 99(5 Pt B):1305-12. . View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/17441929) Zinc-alpha2-glycoprotein expression as a predictor of metastatic prostate cancer following radical prostatectomy J Natl Cancer Inst. 2006 Oct 04; 98(19):1420-4. . View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/17018789) Expression analysis of genes involved in oxaliplatin response and development of oxaliplatin-resistant HT29 colon cancer cells Int J Oncol. 2006 Jul; 29(1):225-35. . View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/16773204) Southwest Oncology Group phase II study of arsenic trioxide in patients with refractory germ cell malignancies Cancer. 2006 Jun 15; 106(12):2624-9. . View in vascular endothelial growth factor: decrease in plasma vascular endothelial growth factor with potential clinical efficacy J Clin Oncol. 2006 Apr 10; 24(11):1712-9. . View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/16520466) Expression and significance of vascular endothelial growth factor receptor 2 in bladder cancer J Urol. 2006 Apr; 175(4):1245-52. . View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/16515971) A of the matrix metalloproteinase inhibitor BMS-275291 in hormone-refractory prostate cancer patients with Clin Cancer Res. 2006 Mar [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/16533781) EphB4 receptor tyrosine kinase is expressed in bladder cancer and provides signals for cell survival Oncogene. 2006 Feb 02; 25(5):769-80. . View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/16205642) Bortezomib plus docetaxel in advanced non-small cell lung cancer and other solid tumors: a phase I California Cancer Consortium trial J Thorac Oncol. 2006 Feb; 1(2):126-34. . View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/17409841) Phase I clinical trial of weekly docetaxel and exisulind, a novel inducer of apoptosis Invest 24(1):79-83. . View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/16379039) Cytokine therapy: Clin Genitourin Cancer. 2005 Dec; 4(3):181-6.. in II trial of tesmilifene plus mitoxantrone and prednisone for hormone refractory prostate cancer: high subjective and objective response in patients with symptomatic metastases J Urol. 2005 Nov; 174(5):1808-13; discussion 1813. [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/16217292) Postchemotherapy residual masses in advanced seminoma: current management and outcomes Expert Rev Anticancer Ther. 2005 Oct; 5(5):869-74. . View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/16221056) Discovery and preclinical evaluation of a novel class of small-molecule compounds in hormone-dependent and -independent cancer cell lines View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/16020668) of EphB4 in mesothelioma and its biological significance Clin Cancer Res. 2005 Jun 15; 11(12):4305-15. . View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/15958611) EphB4 expression and biological significance in prostate cancer Cancer Res. 2005 Jun 01; 65(11):4623-32. . View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/15930280) The current and future application of adjuvant systemic chemotherapy in patients with bladder cancer following cystectomy Urol Clin North Am. 2005 May; 32(2):217-30vii. . View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/15862619) Molecular markers of prostate cancer outcome Eur J Cancer. 2005 Apr; 41(6):858-87. . View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/15808955) Molecular prognostic Int. 2005 Apr; 95(6):739-42. . View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/15794774) Angiogenesis-targeted Prostate Cancer. 3(3):165-73. . View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/15636683) Human immunodeficiency virus-related primary central nervous system lymphoma: factors influencing survival in 111 patients Cancer. 2004 Jun 15; 100(12):2627-36. . View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/15197806) Is year of radical prostatectomy a predictor of outcome in prostate cancer? J Urol. 2004 Feb; 171(2 Pt 1):692-6.. View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/14713788) Microscopic and gross extravesical extension in pathological staging of bladder cancer J Urol. 2004 Feb; 171(2 Pt 1):640-5. . View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/14713777) The future in advanced prostate cancer: take your partners or is the last dance for me? Rev Urol. 2004; 6 Suppl 10:S29-44.. View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/16985929) A preoperative nomogram identifying decreased risk of positive pelvic lymph nodes in patients with prostate cancer J Urol. 2003 Nov; 170(5):1798-803. . View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/14532779) SU5416 plus interferon alpha in advanced renal cell carcinoma: a phase II California Cancer Consortium Study with biological and imaging correlates of angiogenesis inhibition Clin Cancer Res. 2003 Oct 15; 9(13):4772-81. . View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/14581348) Expression of the zinc transporter ZnT4 is decreased in the progression from early prostate disease to invasive prostate cancer Oncogene. 2003 Sep 04; 22(38):6005-12. . View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/12955079) Natural history of surgically treated bladder carcinoma with extravesical tumor extension Cancer. 2003 Sep 01; 98(5):955-61. . View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/12942562) A randomized, prospective clinical trial to assess the potential infection risk associated with the PosiFlow needleless connector J Hosp Infect. 2003 Aug; 54(4):288-93. . View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/12919759) Survival analysis of genome-wide gene expression profiles of prostate cancers identifies new prognostic targets of disease relapse Cancer Res. 2003 Jul 15; 63(14):4196-203. . View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/12874026) Molecular prognostication in bladder current perspective Eur J Cancer. 2003 Jul; 39(11):1501-10. . View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/12855255) Prognostic significance of preoperative factors in localized prostate carcinoma treated with radical prostatectomy: importance of percentage of biopsies that contain tumor and the presence of biopsy perineural invasion Cancer. 2003 Apr serum Proc U S in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/12624183) Downregulation cancer bony metastases does not correlate p53 overexpression 2003; International validation of a preoperative nomogram for prostate cancer recurrence after prostatectomy J Oncol. 2002 Aug 01; 20(15):3206-12. . View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/12149292) and adjunctive bladder cancer Surg Oncol. 2002 Jun; . View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/12031868) Frequent loss of estrogen receptor-beta expression in prostate cancer Cancer Res. 2001 Jul 15; 61(14):5331-5. . View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/11454669) The DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents N Engl J Med. 2001 Mar 344(9):686; author reply 687-8. . View in neoplasia predicts early Cancer Res. 2001 Mar; 7(3):544-50. . View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/11297246) Effect of less frequent bathing of preterm infants on skin flora and pathogen . View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/10819093) Prognostic significance of p53 nuclear accumulation in localized prostate cancer treated with radical prostatectomy Cancer Res. 2000 Mar 15; 60(6):1585-94. . View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/10749127) Cyclin D1 and p16INK4A expression predict reduced survival in carcinoma of the anterior tongue Clin Cancer Res. 1999 Oct; 5(10):2810-9. . mitogen-activated and interleukin-8 production alveolar cells Chest. 1999 Jul; 116(1 Suppl):89S-90S. . View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/10424608) Elevated levels of peritumoral chondroitin sulfate are predictive of poor prognosis in patients treated by radical prostatectomy for early-stage prostate cancer Cancer Res. 1999 May 15; 59(10):2324-8. . View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/10344737) malignancies Australian 1999 Apr 15; 85(8):1758-64. . View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/10223570) Acute renal impairment after near-drowning J Am Soc Nephrol. 1999 Feb; 10(2):382-6. . View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/10215339) An audit of oestrogen implant hormone replacement therapy Aust N Z J Obstet Gynaecol. 1998 dimethyl amiloride on chronic hypoxic pulmonary hypertension in rats Jul; 114(1 Suppl):69S-70S. . View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/9676642) Granulosa cell tumors express erbB4 and are sensitive to the cytotoxic action of heregulin-beta2/PE40 Cancer Res. 1998 May 01; 58(9):1773-8. . View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/9581810) Pharmacokinetic and pharmacodynamic principles of illicit drug use and treatment of illicit drug users Clin Pharmacokinet. 1997 Nov; 33(5):344-400. . View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/9391747) The changing radiographic presentation of bronchogenic carcinoma with reference to cell types Chest. 1996 Dec; 110(6):1474-9. . View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/8989064) Using patient feedback for creating and improving innovative programs J Healthc Qual. 1996 Jul-Aug; 18(4):26-32. . View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/10172679) Drug interactions of clinical importanceAn updated guide. Drug Saf. 1995 Jun; 12(6):393-452. . View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/8527014) Adverse drug reactions and their measurement in the rheumatic diseases J Rheumatol. 1995 May; 22(5):983-8. . Persistence of organ- and iso-antigens in vitro in a long-term culture cell line of colonic carcinoma Pathology. 1982 Oct; 14(4):405-8. . View in [PubMed](https://www.ncbi.nlm.nih.gov/pubmed/6760088) He is a medical oncologist with focus in the field of clinical trials and molecular correlative studies in genitourinary cancer and early therapeutics. David Quinn has published more than 200 papers, reviews and chapters including recent publications in the journals Cancer Research, Clinical Cancer Research, Oncogene, Proceedings of the National Academy of Science, Journal of the National Cancer Institute, Lancet, Lancet Oncology, New England Journal of Medicine and Journal of Clinical Oncology. Dr. Quinn is a reviewer for more than 50 peer-reviewed journals and is on the editorial boards of is on the editorial boards of American Journal of Clinical Oncology, cancer.net (American Society of Clinical Oncology), Clinical Genitourinary Cancer, Bladder Cancer and Annals of Oncology. Dr. Quinn is a member of the NCI Prostate Cancer Task Force, Co-Chair for Genitourinary Cancer in the California Cancer Consortium and is SWOG organ site chair for advanced prostate cancer. He is a full member of the Department of Defense Integration Panel for Prostate Cancer Awards and has been an invited speaker in more than 40 countries. Dr. Quinn's current focus is on clinical trials and translation applications at USC and with SWOG and the California Cancer Consortium, where he has been principal investigator on more than 100 clinical trials for locally advanced and castrate-resistant prostate cancer, high grade urothelial cancer, advanced renal cell cancer, refractory germ cell "}